Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation & Amortization (CF) (2016 - 2026)

Lexaria Bioscience's Depreciation & Amortization (CF) history spans 12 years, with the latest figure at $35967.0 for Q1 2026.

  • Quarterly results put Depreciation & Amortization (CF) at $35967.0 for Q1 2026, up 1479.58% from a year ago — trailing twelve months through Feb 2026 was $495.0 (up 105.36% YoY), and the annual figure for FY2023 was $145397.0, up 41.55%.
  • Depreciation & Amortization (CF) for Q1 2026 was $35967.0 at Lexaria Bioscience, up from -$66427.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $70928.0 in Q3 2023 to a low of -$66427.0 in Q3 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $24731.0 (2022), against an average of $16009.5.
  • The sharpest move saw Depreciation & Amortization (CF) tumbled 184.29% in 2024, then skyrocketed 1479.58% in 2026.
  • Year by year, Depreciation & Amortization (CF) stood at $24730.0 in 2022, then grew by 16.37% to $28778.0 in 2023, then increased by 15.35% to $33195.0 in 2024, then tumbled by 300.11% to -$66427.0 in 2025, then surged by 154.15% to $35967.0 in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $35967.0, -$66427.0, and $30955.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.